CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

GigaGen’s prior work with the DOD produced polyclonal antibodies that can neutralize two botulinum neurotoxins, which are ...

The firm will enter studies this month aimed at obtaining CLIA waiver for its FDA-cleared FebriDx assay to distinguish bacterial from non-bacterial infections.

The BARDA funding will support studies to validate the Melbourne, Australia-headquartered firm's flagship FebriDx rapid host-response respiratory infection test in low complexity settings and ...

The contract through the Center for the Biomedical Advanced Research and Development Authority, or BARDA, is an opportunity for GigaGen to deliver not only a life-saving drug but a new class of ...

Track the latest bird flu vaccine news, investments, and deals as biotechs respond to rising U.S. cases with innovative ...

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting ...

Biomedical Advanced Research and Development Authority (BARDA) and CSL Seqirus will expand their reserves of MF59® adjuvant to the equivalent of 40 million doses as part of the National Pre ...

Gigagen Inc., a subsidiary of Grifols SA, has been awarded a contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a recombinant polyclonal antibody therapy ...

Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating ...